Ondine Biomedical Inc (AIM:OBI) said its Steriwave photodisinfection technology has been approved for sale and use in Mexico.
Mexico is a key strategic target said Ondine, with a population of 129mln and a burgeoning medical tourism sector.
Ondine estimates this tourism market alone is worth almost US$7bn annually.
Steriwave eliminates nasal pathogens that can cause healthcare-associated infections (HAIs).
In a statement, Carolyn Cross, Ondine’s chief executive, commented: "With significant global backlogs and high costs of various types of medical procedures, medical tourism is likely to be on the rise over the coming years, as foreign medical tourists seek state-of-the-art medical services at affordable prices."
"The great advantage of our photodisinfection therapy is that it not only spares patients the trauma of an infection, but it can also reduce patient waiting lists by reducing hospital readmissions rates and decreasing the average length of stay in hospital.
“The Mexican healthcare market is of strategic interest to our company and is of personal interest to me,” she said.